Remove 2028 Remove Drug Development Remove Regulations Remove Trials
article thumbnail

Highs and lows of drug repurposing 

Drug Discovery World

It’s also why pharmaceutical companies will look to acquire smaller biotechs and drug discovery companies, because a lot of the legwork into finding a suitable molecule for a disease has already been done. . This level of growth is unsurprising for an industry which will always look to the latest opportunities to drive science. .

article thumbnail

How AI in pharma can live up to the hype 

Drug Discovery World

In fact, the market research firm, Bekryl, predicts that AI has the potential to offer over $70 billion in savings for the drug discovery process by 2028. . NEC, the Japanese IT and electronics corporation, has pivoted towards drug discovery with a focus on personalised medicines. billion in 2021, an increase of 79% from 2020.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Article FDA Thank You The FDA rejected a psychedelic sponsor’s bid for approval. Here are six industry takeaways

Agency IQ

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. Panel members flagged potential issues with variability between providers.

FDA 40
article thumbnail

Article FDA Thank You Diagnostics landscape analysis: Key issues and a look ahead at 2024

Agency IQ

Diagnostics landscape analysis: Key issues and a look ahead at 2024 Diagnostic regulation in the U.S. Following significant policy proposals in recent years, 2024 is gearing up to be a profoundly impactful year for diagnostics developers and the policymakers who regulate them. is a constantly evolving topic. In the U.S.,

FDA 40